Danaher in $5.7 billion deal for antibody specialist Abcam

Danaher, a technology development firm focused on life sciences, diagnostics, food, and water management, has agreed to acquire the antibody specialist Abcam for $5.7 billion. Abcam will operate as a stand-alone company and brand in Danaher’s life sciences business group. Founded in 1998 and headquartered in Cambridge, England, Abcam develops antibodies, reagents, biomarkers and assays for use in drug discovery and diagnostics applications. “Danaher shares our passion to help life science researchers achieve their mission faster and their operating company model allows us to continue to pursue our strategy,” says Abcam CEO Alan Hirzel in a press release. The deal is expected to be completed by mid-2024.